OxTalks is Changing
Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
Early innovation in drug platforms: antibodies and bicyclic peptides
Sir Gregory Winter FRS is Master of Trinity College Cambridge and was until recently a member of the Medical Research Council’s Laboratory of Molecular Biology (LMB) in Cambridge. He is a scientist, inventor and entrepreneur. He is a pioneer of the science of protein engineering, and in particular of technologies for making pharmaceutical antibodies. Such antibodies have proved useful for treatment of cancer and immune disorders, and now comprise many of the world’s top selling pharmaceutical drugs. In order to see his technologies applied, Sir Gregory founded Cambridge Antibody Technology and Domantis (both acquired in 2006 by AstraZeneca and GSK respectively), and most recently Bicycle Therapeutics, which is developing bicyclic peptides with chemical warheads for treatment of cancer.
Date:
25 September 2017, 12:00
Venue:
Kennedy Institute of Rheumatology, Headington OX3 7FY
Venue Details:
Bernard Sunley Lecture Theatre
Speaker:
Sir Gregory Winter FRS (Master of Trinity College Cambridge)
Organiser:
Laura Hume (Kennedy Institute of Rheumatology)
Host:
Professor Fiona Powrie (Kennedy Institute of Rheumatlogy)
Booking required?:
Not required
Audience:
Members of the University only
Editor:
Laura Sanchez Lazo
